Castle Biosciences, Inc.
CSTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $83,043 | $86,188 | $87,988 | $86,311 |
| % Growth | -3.6% | -2% | 1.9% | – |
| Cost of Goods Sold | $18,704 | $17,626 | $16,383 | $16,183 |
| Gross Profit | $64,339 | $68,562 | $71,605 | $70,128 |
| % Margin | 77.5% | 79.5% | 81.4% | 81.3% |
| R&D Expenses | $12,960 | $12,787 | $12,588 | $11,677 |
| G&A Expenses | $0 | $22,942 | $21,812 | $19,552 |
| SG&A Expenses | $55,907 | $58,065 | $58,620 | $49,965 |
| Sales & Mktg Exp. | $0 | $35,123 | $36,808 | $30,413 |
| Other Operating Expenses | $2,276 | $1,961 | $28,325 | $4,436 |
| Operating Expenses | $71,143 | $72,813 | $99,533 | $66,078 |
| Operating Income | -$6,804 | -$4,251 | -$27,928 | $4,050 |
| % Margin | -8.2% | -4.9% | -31.7% | 4.7% |
| Other Income/Exp. Net | $6,418 | $4,108 | $1,657 | $3,835 |
| Pre-Tax Income | -$386 | -$143 | -$26,271 | $7,885 |
| Tax Expense | $115 | -$4,666 | -$423 | -$1,705 |
| Net Income | -$501 | $4,523 | -$25,848 | $9,590 |
| % Margin | -0.6% | 5.2% | -29.4% | 11.1% |
| EPS | -0.017 | 0.16 | -0.9 | 0.34 |
| % Growth | -110.8% | 117.8% | -364.7% | – |
| EPS Diluted | -0.02 | 0.15 | -0.9 | 0.32 |
| Weighted Avg Shares Out | 25,050 | 28,914 | 28,609 | 28,126 |
| Weighted Avg Shares Out Dil | 29,073 | 29,545 | 28,609 | 30,200 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,809 | $2,944 | $3,099 | $3,372 |
| Interest Expense | $0 | $21 | $17 | $92 |
| Depreciation & Amortization | $5,631 | $3,414 | $29,764 | $5,768 |
| EBITDA | $5,245 | $3,292 | $3,510 | $13,745 |
| % Margin | 6.3% | 3.8% | 4% | 15.9% |